Abstract:To investigate the efficacy and the roles of immune interruptions on blocking mother-to-infant transmission of hepatitis B virus (HBV),667 pregnant women who were seropositive for hepatitis B surface antigen (HBsAg) were enrolled. According to the lab test results of HBV e antigen (HBeAg) and HBV DNA in the mothers, the mothers were divided into either HBeAg-positive group or HBeAg-negative group, and either HBV DNA-positive group or HBV DNA-negative group. Depending on whether the mothers were receiving hepatitis B immunoglobulin (HBIG) once a month during the third trimester of pregnancy, they were divided into either the HBIG-receiving group or the non-HBIG-receiving group. All infants received regular passive and active HBV immunization after birth. Infant serum HBV markers were determined 8-12 months after birth. Twenty infants born to HBsAg-positive mothers were infected with HBV and the failure rate of immune interruptions was 3.0%. The failure rate of immune interruptions in the HBeAg-positive group was 8.7%, which was significantly higher than that observed in HBeAg-negative group 0.2% (P<0.001). However, the HBV surface antibody (HBsAb) positive rates of the infants between the two groups were not statistically different (P=0.988). The overall failure rate of immune interruptions of infants born to the HBV DNA-positive group was 8.1%, and the infants infected with HBV were all born to the mothers whose serum HBV DNA levels were above 6 log10 copies/ml. There were no statistical differences in the incidence of perinatal HBV infection between mothers receiving HBIG and those not receiving HBIG (3.7% vs 2.7%, P=0.479). No statistical differences were seen in HBsAb positive rates versus vaccination of the infants between the two groups (84.4% vs 82.4%, P=0.519). Among HBeAg-positive pregnant women receiving HBIG, the failure rate of immune interruptions in their infants was 8.4%, compared with 8.9% in those who did not receive HBIG, with no statistical differences (P=0.892). Importantly, 10 out of 11 infants who were infected with HBV were already serum HBsAg-positive immediately after birth, suggesting intrauterine infection either via venous or cord blood. These results indicate that preventative vaccine immunization plus HBIG administration does not block intrauterine transmission of HBV. Approaches to decrease the serum HBV DNA load in pregnant women by antiviral treatment may efficiently block mother-to-infant transmission.

The relationship of maternal hepatitis B e antigen and response to vaccination of infants born to women with chronic infection

Monitoring the Efficacy of Infant Hepatitis B Vaccination and Revaccination in 0- to 8-Year-old Children: Protective Anti-Hbs Levels and Cellular Immune Responses.

Effect of Prophylactic Antiviral Intervention on T Cell Immunity in Hepatitis B Virus-Infected Pregnant Women

Immune Response to Hepatitis B Vaccine in Children Born to HBsAg Positive Mothers: a Meta-Regression Analysis

Transplacentally Acquired Maternal Antibody Against Hepatitis B Surface Antigen in Infants and Its Influence on the Response to Hepatitis B Vaccine.

Influence of maternal antibody against hepatitis B surface antigen on active immune response to hepatitis B vaccine in infants.

No response to hepatitis B vaccine in infants born to HBsAg(+) mothers is associated to the transplacental transfer of HBsAg

Inhibition of Maternal Antibody to Hepatitis B Surface Antigen on Antibody Response to Hepatitis B Vaccine in Infants

Maternal Hepatitis B E Antigen Can Be an Indicator for Antiviral Prophylaxis of Perinatal Transmission of Hepatitis B Virus

Relationship Between Maternal HBsAg, HBeAg Titres and Hepatitis B Vaccine Failure in Infants Born to HBV Carrier Mothers

Is hepatitis B e antigen in cord blood an immunotolerogen playing a critical role in the pathogenesis of chronic hepatitis B?

Transformation of Hepatitis B Serologic Markers in Babies Born to Hepatitis B Surface Antigen Positive Mothers

Comparison of antibody response to hepatitis B vaccination in infants with positive or negative maternal hepatitis B e antigen (HBeAg) in cord blood: implication for the role of HBeAg as an immunotolerogen.

The efficacy of immune interruptions on blocking mother-toinfant transmission of hepatitis B virus

Protective effect of regular immunoprophylaxis on infants against perinatal hepatitis B virus infection

Long-term Protection of Infants Against Hepatitis B by Neonatal Immunoprophylaxis Born from Mothers Infected with Hepatitis B Virus

Further Improving the Efficacy of HBV Vaccination in the Prevention of Mother-to-infant Transmission of Hepatitis B

Influencing factors of high immune response in newborns induced by hepatitis B vaccine in Haidian District, Beijing

Impaired trophoblast Toll-Like Receptor 3 signaling pathway involves in hepatitis B vaccine non- or hypo-response of infants born to HBsAg-positive mothers

Epidemiological trends and virological traits of hepatitis B virus infection in pregnant women and neonates

Virological Determinants of Spontaneous Postpartum E Antigen Seroconversion and Surface Antigen Seroclearance in Pregnant Women Infected with Hepatitis B Virus.